Help Desk
10 Am-7 Pm (Mon-Sat)
Contact
+91 728 787 4503
cancermeds-list
cancermeds-noimage

DACOTIN 50 MG INJ ( PC , 1 )

Manufactured by: Dr. Reddy’s Laboratories Ltd

. 3117.00/- . 3470.00/- 10.17 % OFF You Save : . 353.00/-
Availability : In stock

DESCRIPTION

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

CATEGORIES

Antineoplastic Agents Immunosuppressive Agents Antineoplastic and Immunomodulating Agents Platinum Compounds Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 CYP1A2 Inducers CYP2E1 Inhibitors CYP2E1 Inducers CYP2E1 Inducers (strong)

CHEMICAL FORMULA

C8H12N2O4Pt

COMPOSITION

Oxaliplatin 50 MG

INDICATION

Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.

PHARMACODYNAMICS

Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

MECHANISM

Oxaliplatin undergoes nonenzymatic conversion to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and transcription. Cytotoxicity is cell-cycle nonspecific.

ABSORPTION

Bioavailability is complete following intravenous administration. When a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m^2 is given, the peak serum concentration was 0.814 mcg/mL.

VOLUME DISTRIBUTION

440 L [single 2-hour IV infusion at dose of 85 mg/m^2] At the end of a 2-hour infusion of oxaliplatin, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine.

METABOLISM

Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. There is no evidence of cytochrome P450-mediated metabolism in vitro.

ROUTE ELIMINATION

The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of oxaliplatin, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%.

HALF LIFE

The decline of ultrafilterable platinum levels following oxaliplatin administartion is triphasic, with two distribution phases: t1/2a; 0.43 hours and t1/2ß; 16.8 hours. This is followed by a long terminal elimination phase that lasts 391 hours (t1/2?).

TOXICITY

There have been five cases of oxaliplatin overdose reported. One patient received two 130 mg/m2 doses of oxaliplatin (cumulative dose of 260 mg/m2) within a 24-hour period. The patient experienced Grade 4 thrombocytopenia (<25,000/mm3) without any bleeding, which resolved. Two other patients were mistakenly administered oxaliplatin instead of carboplatin. One patient received a total oxaliplatin dose of 500 mg and the other received 650 mg. The first patient experienced dyspnea, wheezing, paresthesia, profuse vomiting and chest pain on the day of administration. She developed respiratory failure and severe bradycardia, and subsequently did not respond to resuscitation efforts. The other patient also experienced dyspnea, wheezing, paresthesia, and vomiting. Most common adverse reactions (incidence = 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis.

FOOD INTERACTIONS

Avoid Alcohol

SIDE EFFECTS

Chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu. Numbness and tingling of the feet or hands caused by cold. Avoid cold temperatures, cold food or drinks, cold flooring, and the refrigerator or freezer for at least 5 days after this drug is given. Throat tightness, feeling of not being able to swallow or breathe. This goes away by itself. Avoid anything cold for at least 5 days after this drug is given. Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. Loose stools (diarrhea). Headache. Cough. Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them. Hard stools (constipation). Belly pain. Anemia, low white blood cell count, and low platelet count. Fever. Feeling tired or weak. High blood pressure. Harm to the liver may rarely happen. Harm to the lungs may rarely happen.